Tag: Evolut Low Risk
ACC 2023: Benefit of TAVI “consistent” over first three years in low risk patients
Three-year results fr...
Two-year Evolut Low Risk trial data shows “very favourable outcomes” for TAVI compared with SAVR
John Forrest (New Ha...
Evolut gets CE mark in low-risk patients and new labelling for bicuspid use
Medtronic has been aw...
